Kymera Therapeutics

OverviewSuggest Edit

Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.

TypePrivate
Founded2017
HQWatertown, MA, US
Websitekymeratx.com

Latest Updates

Employees (est.) (Jul 2021)105(+9%)
Job Openings29
Cybersecurity ratingAMore

Key People/Management at Kymera Therapeutics

Nello Mainolfi

Nello Mainolfi

Founder, President, Chief Executive Officer & Director
Jared Gollob

Jared Gollob

Chief Medical Officer
Bruce Jacobs

Bruce Jacobs

Chief Financial Officer
Richard Chesworth

Richard Chesworth

Chief Scientific Officer
Ashwin Gollerkeri

Ashwin Gollerkeri

Senior Vice President, Head of Development, Director
Brian Albarran

Brian Albarran

Vice President, Strategy and Operations
Show more

Kymera Therapeutics Office Locations

Kymera Therapeutics has an office in Watertown
Watertown, MA, US (HQ)
200 Arsenal Yards Blvd #230
Show all (1)

Kymera Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Kymera Therapeutics total Funding

$197 m

Kymera Therapeutics latest funding size

$102 m

Time since last funding

a year ago

Kymera Therapeutics investors

Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Show all financial metrics

Kymera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Kymera Therapeutics Online and Social Media Presence

Embed Graph

Kymera Therapeutics News and Updates

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice Pr…

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten public…

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public…

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public o…

Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?

NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Kymera Therapeutics Blogs

13th Annual T-Cell Lymphoma Forum, July 8-10, 2021

Poster: Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL The post 13th Annual T-Cell Lymphoma Forum, July 8-10, 2021 appeared first on Kymera Therapeutics.

The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation

The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis - the promise of these advantages has ma…

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021

Presentation: KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models The post 16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021 appe…

Marking Kymera’s 5-Year Anniversary Video

The post Marking Kymera’s 5-Year Anniversary Video appeared first on Kymera Therapeutics.

Marking Kymera’s 5-Year Anniversary

Kymera was founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of a powerful new class of medicines based on targeted protein degradation (TPD). As we celebrate Kymera’s five-year anniversary, I look back and reflect on the inspiratio…

Ligase Targeting Drug Development Summit, May 25 – 27, 2021

Poster Presentation: Drugging Tissue-Restricted E3 Ligases The post Ligase Targeting Drug Development Summit, May 25 – 27, 2021 appeared first on Kymera Therapeutics.
Show more

Kymera Therapeutics Frequently Asked Questions

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2017.

  • Who are Kymera Therapeutics key executives?

    Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.

  • How many employees does Kymera Therapeutics have?

    Kymera Therapeutics has 105 employees.

  • Who are Kymera Therapeutics competitors?

    Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Synspira.

  • Where is Kymera Therapeutics headquarters?

    Kymera Therapeutics headquarters is located at 200 Arsenal Yards Blvd #230, Watertown.

  • Where are Kymera Therapeutics offices?

    Kymera Therapeutics has an office in Watertown.

  • How many offices does Kymera Therapeutics have?

    Kymera Therapeutics has 1 office.